KROS Q1 2024 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83,000

Gross Profit

$83,000100.0% margin

Operating Income

-$48M-58413.3% margin

Net Income

-$43M-51944.6% margin

EPS (Diluted)

$-1.46

QoQ Revenue Growth

-42.0%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$46M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$486M

Total Liabilities

$32M

Stockholders' Equity

$454M

Cash & Equivalents

$442M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83,000	$0	—
Gross Profit	$83,000	$0	—
Operating Income	-$48M	-$39M	-24.7%
Net Income	-$43M	-$36M	-20.4%

Revenue Segments

Service, Other

$83,000100%